Sinovac

WHO approves China's Sinovac COVID-19 jab for emergency use, recommends use for adults

The WHO, however, said there should be no upper age limit on the vaccine as there is 'no reason to believe it has a different safety profile' in older generations

Pfizer, Moderna, Astrazeneca, Bharat Biotech, other COVID-19 vaccines in use or getting close

The shots were all tested differently, and some were allowed to go into use even before they were rigorously tested.

China wanted to show off its COVID-19 vaccines to the world, but the move is backfiring

A YouGov survey this month of roughly 19,000 people in 17 countries and regions showed that most were distrustful of a COVID-19 vaccine made in China

Disappointing results from Chinese CoronaVac trial pose a setback for developing nations

Many nations that have ordered CoronaVac are relatively poor, desperate to halt the pandemic and protect their population.

Chinese firm Sinovac to boost production capacity to 600 mn doses for Covid-19 efforts

Indonesia has received 1.2 million doses of its experimental vaccine and is expected to approve it for use soon.

Turkey announces vaccination plan, to get first shipment of China'a CoronaVac after 11 Dec

Turkey's health minister Fahrettin Koca said the vaccine will be administered in two doses per person and is expecting delivery of at least 10 million doses in December

Coronavirus vaccine: Lancet study suggests Sinovac candidate is safe and effective in phase I and II trials

CoronaVac is an inactivated vaccine (vaccine that contains a virus unable to cause disease) that had earlier shown positive results in mice, primates and rats by producing neutralising antibodies against SARS-CoV-2

SinoVac announces Coronavirus vaccine to be ready for distribution by 2021

While the vaccine has not yet passed the phase 3 clinical trials, SinoVac has already injected thousands of people in China under an emergency use provision.

CanSino Biologics in talks with Russia, Brazil, Chile, Saudi Arabia to launch Phase III trial of its COVID-19 vaccine

Qiu Dongxu co-founder of CanSino said its new factory under construction in China will allow it to produce 100-200 million vaccine doses per year by early 2021.